Malignant neoplasm is believed to be one of the extended conditions of neoplasm. It is a form of cancer that develops an abnormal growth of tissues usually leading to the formation of a tumor. The primary cause of this disease is understood as damaging of DNA under certain circumstances that further escalates to a stage of cancer. The very beginning of malignant neoplasm is the occurrence of abnormal patterns of growth in the tissue known as dysplasia or metaplasia.
Higher Prevalence of Malignant Neoplasm in Geriatric Population Driving the Market Growth
The global cancer incidences have increased to a considerable number over the past few decades owing to a rise in the geriatric population, increasing life expectancy and changing lifestyle. In addition, factors such as advanced cancer diagnostics and early initiation of the treatment are fuelling the global malignant neoplasm therapeutics market. Development of targeted therapies are revolutionizing the conventional concepts of cancer treatment and are likely to get higher preference in the coming years. Moreover, a higher success ratio of these latest cancer drugs compared to traditional anti-carcinogenic treatment is expected to further drive the market growth in the near future. These latest drugs are capable of countering more than one type of cancer. For example ‘imatinib’, which was first developed for treating a single type of cancer was later found effective on multiple cancer types.
Novelty in cancer treatment has significantly influenced the present treatment models. However, a complete cure for the disease is still not ascertained. Further, many of the advanced treatment models are often expensive and only available in developed regions of the world. In some case, delay in integration of the novel drugs into current treatment methods limit the options for the patient. Other factors such as price risk and credibility of the drugs are few of the other concerns for the market.
Over the years, the subject of oncology has received paramount attention from biomedical researchers, health care experts and pharmaceutical manufacturers. Owing to a severe need for effective treatment of cancer, heavy investments are being made in further research and development of the particular subject. Many of the pharmaceutical companies such as Novartis International AG and Pfizer Inc. are introducing a range of anti-carcinogenic drugs under their brand names promising to be more efficient. The global malignant neoplasm treatment market has become increasingly competitive in the recent years with more player joining in. Currently, most drug manufacturers offer two primary cancer therapeutic programs, namely cytostatic hormonal treatments and antineoplastics.
Malignant Neoplasm Therapeutics Market: Regional Segmentation
On the basis of region, the global malignant neoplasm therapeutics market has been segmented into six key regions namely North America, Western Europe, Eastern Europe, Asia Pacific (APAC), Latin America, and the Middle East & Africa. North America is considered as one of the largest market of malignant neoplasm therapeutics owing to a strong presence of drug manufacturers in the region and availability of advanced healthcare facilities. In terms of value, the U.S accounts for a healthy portion of the global malignant neoplasm therapeutics market attributed to the growing demand for cancer treatment in the country. In addition, Europe is one of the other regions where the market is growing at a considerable rate and is expected to continue a similar in trend in the coming years.
Few of the key players identified in the global malignant neoplasm therapeutics market include F. Hoffmann-La Roche AG, Novartis International AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Takeda Pharmaceutical Company Ltd, Pfizer Inc. Bayer AG, Amgen, AbbVie Inc and Celgene Corporation.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.